Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Allergan (NYSE:AGN) and Dicerna Pharma (NASDAQ:DRNA).
Allergan (AGN)
In a report released today, Elliot Wilbur from Raymond James maintained a Buy rating on Allergan, with a price target of $232. The company’s shares closed on Friday at $188.22.
According to TipRanks.com, Wilbur is a 4-star analyst with an average return of 4.5% and a 49.3% success rate. Wilbur covers the Healthcare sector, focusing on stocks such as Amphastar Pharmaceuticals, ANI Pharmaceuticals Inc, and Antares Pharma.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Allergan with a $196.50 average price target, implying a 4.4% upside from current levels. In a report issued on September 12, Deutsche Bank also reiterated a Buy rating on the stock with a $210 price target.
.
See today’s analyst top recommended stocks >>
Dicerna Pharma (DRNA)
B.Riley FBR analyst Madhu Kumar maintained a Hold rating on Dicerna Pharma today and set a price target of $13.50. The company’s shares closed on Friday at $17.69, close to its 52-week high of $17.98.
According to TipRanks.com, Kumar is a 5-star analyst with an average return of 25.8% and a 53.2% success rate. Kumar covers the Healthcare sector, focusing on stocks such as Spring Bank Pharmaceuticals Inc, Arbutus Biopharma Corporation, and Deciphera Pharmaceuticals Inc.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Dicerna Pharma with a $20.30 average price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
